🟢 Eupraxia Pharmaceuticals is trading 13.2% up in after-hours trading

Eupraxia Pharmaceuticals is trading at $7.80, up +13.21% in after-hours trading; no clear company-specific catalyst was identified.

• The latest releases listed on Eupraxia’s investor-relations page are dated October 22 and October 15.
• The October 15 release reported reaching the RESOLVE trial’s 120-patient enrollment target; it is not a new catalyst for this move.
• Market context shows a broad technology rebound, but evidence does not establish that it explains the biotech stock’s after-hours rise.